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Signal detection requires ratings reliability throughout a clinical trial. The conﬁrmation of site-
based rater scores by a second, independent and blinded rater is a reasonable metric of ratings
reliability.
We used audio-digital pens to record site-based interviews of the Montgomery-Asberg
Depression Rating Scale (MADRS) in a double-blind, placebo controlled trial of a novel
antidepressant in treatment resistant depressed patients. Blinded, site-independent raters
generated “dual” scores that revealed high correlations between site-based and site-
independent raters (r=0.940 for all ratings) and high sensitivity, speciﬁcity, predictive values,
and kappa coefﬁcients for treatment response and non-response outcomes using the site-based
rater scores as the standard. The blinded raters achieved an 89.4% overall accuracy and 0.786
kappa for matching the treatment response or non-response outcomes of the site-based raters.
A limitation of this method is that independent ratings depend on the quality of site-based
interviews and patient responses to the site-based interviewers. Nonetheless, this quality
assurance strategy may have broad applicability for studies that use subjective measures and
wherever ratings reliability is a concern. “Dual” scoring of recorded site-based ratings can be a
relatively unobtrusive surveillance strategy to conﬁrm scores and to identify and remediate
rater “outliers” during a study.
& 2014 Elsevier B.V. and ECNP. Open access under CC BY-NC-ND license.o.2014.08.016
CNP.
t Suite 600, Boston, MA 02108, USA. Tel.: +1 617 824 0800.
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More than 50% of recently conducted randomized, placebo-
controlled trials of antidepressant medications have failed
to differentiate the candidate drug from placebo (Hooper
and Amsterdam, 1999; Khan et al., 2002, 2003; Papakostas
and Fava, 2009; Khin et al., 2011). Beyond the actual
efﬁcacy of the candidate drug, clinical trials can fail
because of poor study design as well as study execution
(Fava et al., 2003). Some of the inherent aspects of the
design of randomized clinical trials may inﬂuence response
expectations and may reinforce placebo effects. For
instance, both the requisite consenting process and the
ritualized, repetitive, and often supportive study proce-
dures conducted at each visit can foster expectations and
conditioned learning (Miller et al., 2009). The true drug
effect may be only a fraction of the total symptomatic
change that occurs during the course of a study (Lambert,
1992; Kirsch and Sapirstein, 1998; Miller et al., 2009). Some
placebo response is inevitable in a well-conducted double-
blind trial. The management of these inherent challenges
requires ratings reliability (scoring accuracy and ratings
consistency) throughout the trial to improve the predictive
value of the test. In fact, it is well established that ratings
reliability is a key factor to achieve study success (Muller
and Szegedi, 2002; Kobak et al., 2005, 2007; Targum, 2006).
Kobak et al. (2007) identiﬁed poor inter-rater reliability,
poor interview quality, and rater scoring biases as major
factors causing clinical trials to fail. It has also been shown
that poor ratings reliability adversely affects the power to
detect a signiﬁcant signal (Leon and Marzak, 1995; Perkins
et al., 2000; Muller and Szegedi, 2002). One method to
evaluate ratings reliability is to examine ratings precision
(reproducibility of the same assessment) by using two
independent raters to assess the same patient. We have
adopted this two-rater strategy and explored the utility of
“dual” (paired) scoring by using blinded, site-independent
raters to score audio-digital recordings of site-based inter-
views in studies of Major Depressive Disorder (MDD) and
schizophrenia (Asgharnejad et al., 2012; Targum et al.,
2012; Leigh-Pemberton et al., 2014).
In this study, we examined the sensitivity, speciﬁcity,
predictive values, and kappa coefﬁcients of blinded, site-
independent “dual” scores to match the treatment outcome
results of site-based scores of the same patient in a double-
blind, placebo-controlled trial of treatment resistant
depressed patients.2. Experimental procedures
Data for this analysis of “dual” (paired) ratings came from a quality
assurance program that was employed in a study of CX157 (TriRimas)
versus placebo for patients with treatment resistant depression
(Clinicaltrials.gov identiﬁer: NCT00739908). CX157 is a reversible
and selective monoamine oxidase-A inhibitor (Anderson et al.,
1993). Eligible subjects met DSM-IV-TR criteria for Major Depressive
Disorder (MDD) and had sufﬁcient documentation of inadequate
treatment responses to at least one but no more than three adequate
courses of antidepressant medication in their current episode as
measured by the MGH-antidepressant treatment response question-
naire (APA, 1994; Chandler et al., 2010). The primary efﬁcacy measure
was the change in the total MADRS score from baseline to endpoint inthe modiﬁed intent to treat (mITT) population. The mITT population
included those subjects in the safety analysis set who took at least one
dose of study medication and had MADRS total scores at randomization
and at least one post-treatment visit.
The study was conducted in compliance with Institutional Review
Board (IRB), informed consent regulations, and International Con-
ference on Harmonization (ICH) for Good Clinical Practice (GCP)
Guidelines at 29 clinical trial sites in the United States. All potential
subjects signed informed consent to participate in the study.
Eligible patients were given either CX157 at 125 mg B.I.D. or
matching placebo tablets in a 1:1 double-blind, randomization
design for 6 weeks.
Study eligibility included a minimum total score on the 17-item
Hamilton depression rating scale (HamD-17) at the screen visit
(Hamilton, 1960). However, the primary efﬁcacy measure for the
study was the Montgomery-Asberg Depression Rating Scale (MADRS)
that was administered using a Structured Interview Guide (SIGMA)
at the baseline visit and the post-randomization visits at weeks 1, 2,
4, and 6 (Montgomery and Asberg, 1979; Williams and Kobak, 2008).
The guide was developed to enhance inter-rater reliability by
standardizing the prompts asked by each rater for each of the ten
MADRS items.
All site-based and site-independent raters participated in a
comprehensive rater training and certiﬁcation program that
included didactic presentations, observation of expert MADRS video
interviews, and demonstration of MADRS scoring competency via
inter-rater reliability (IRR) assessments of two MADRS video inter-
views. Light's kappa's (a multi-rater version of Cohen's kappa) was
used to calculate IRR (Warrens, 2010). Site-based raters were also
required to demonstrate interviewing competency skills via mock
MADRS interviews. As part of this program, the site-based raters
were trained to conduct the MADRS interviews using an audio-
digital recording pen. The pens simultaneously audio-record the
MADRS interview and digitally copy accompanying written notes
that are captured on specially manufactured source books. The
recorded interviews were electronically forwarded to Clintara LLC
(Boston, MA) for random assignment to six site-independent raters
who had also completed the MADRS training requirements. The site-
independent raters were blinded to the study visit and trial site and
generated their “dual” scores by listening to the audio recording
and reading the site-based rater's accompanying digital notes. The
digital notes sent to the blinded rater did not include the site-based
rater's scores.
All patients consented to audio-digital recording of site-based
MADRS interviews as part of their consent to participate in the
study. In this study, 100% of the interviews were recorded and
collected throughout the study as part of the quality control
program and 20–25% of the submitted recordings were randomly
assigned for scoring by the site-independent raters. Initially, “dual”
scoring was randomly assigned to all sites and all raters. As the
study progressed, some rater “outliers” were identiﬁed in-study for
additional “dual” ratings surveillance. All recordings were reviewed
for completeness and sound quality prior to “dual” scoring. As part
of the review plan, a higher percentage of baseline and week 6
(endpoint) MADRS interviews were independently scored in order to
facilitate treatment outcome comparisons.
Site-based treatment outcome data for this study has been
reported elsewhere (Targum et al., 2014). In this analysis, we
examined the scoring variance, intra-class correlation, and absolute
discordance between the available “dual” (paired) site-based and
site-independent MADRS scores. Scoring discordance reﬂects the
deviation (total score difference) of the site-independent scores
from the paired site-based MADRS scores in either direction. The
discordance rate was calculated as the number of “dual” scores
that were greater than 1 standard deviation of the mean total
MADRS score for the total mITT population at baseline (46 points in
this study). The choice of a broad, rather than narrow concordance
range was based upon the quality assurance (QA) focus of the
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In addition, we recognized that some scoring variability was
inevitable between live site-based interviews and independent
raters who listen to the recordings but do not observe the patient
during these interviews.
Throughout the study, site-based rater “outliers” whose “dual”
scores were discordant were identiﬁed for remediation. A second,
independent rater listened to the ﬂagged “discordant” interviews
to afﬁrm the scoring discordance. Rater remediation included
telephone discussions with the site-based rater to review individual
scoring differences and interview style, and was followed by
increased vigilance of their subsequent interviews. Raters whose
scoring discordance did not improve could be removed from the
study. As part of the overall QA program, ongoing “dual” data from
all raters were accumulated and reviewed throughout the study to
ascertain whether additional, mid-study rater training was neces-
sary for the whole group.
In this study, treatment response was deﬁned as a MADRS score
improvement of Z50% between the baseline and endpoint measure-
ment. We examined the sensitivity, speciﬁcity, positive predictive
value (PPV) and negative predictive value (NPV) of the blinded, site-
independent raters to match the response/non-response treatment
outcome status of the site-based rater MADRS scores used as the
standard for comparison (Bland, 2000). Finally, overall response
accuracy for each group and the entire sample was calculated as
all true CX157 positives (treatment responders) and true placebo
negatives (placebo non-responders) divided by all “dual” scored
subjects based on the site-based outcomes as the standard (Bland,
2000). Additional statistical analyses included intra-class correlation
(ICC), the kappa coefﬁcient, and Student's t test as appropriate.3. Results
3.1. Treatment results for the mITT population
597 subjects were screened and 360 were randomized to
either CX157 treatment (n=182) or placebo (n=178). 353
patients qualiﬁed for the modiﬁed intent to treat popula-
tion: mITT (CX157, n=176; placebo, n=177). At the base-
line (randomization) visit, the mean total MADRS score for
the mITT population was 32.576.1 (SD) for CX157 and
32.076.3 for the placebo group. At week 6, the mean total
MADRS score in the mITT population was 23.3712.81 (SD)
for CX157 and 22.2712.3 for the placebo group. Treatment
response analyses for the mITT population revealed a 33.0%
positive response for the CX157 group and a 31.1% placebo
response. As previously reported, LOCF and MMRM analyses
of the mITT population revealed no statistically signiﬁcant
differences in the changes of the total MADRS score
between groups at any time point from randomization to
week 6 (Targum et al., 2014).3.2. MADRS interview length
There were 1664 MADRS interviews completed across 5
study visits (the baseline visit and four post-randomization
visits). The mean interview length of the recorded MADRS
interviews was 25:1378:36 (SD) minutes at baseline and
19:3177:49 for all post-randomization interviews. The
mean post-randomization MADRS interview length was sig-
niﬁcantly less than the baseline interview (p=0.0001).
Interview lengths ranged from 9:50 to 63:20 min at baseline
and 6:20 to 47:33 min post-randomization (medianinterview length was 23:30 min at baseline and 16:17 min
post-randomization). MADRS interview length was not cor-
related with symptom severity as measured by the total
MADRS score at baseline (r=0.035) and was weakly
correlated with severity at the post-randomization visits
(r=0.306).3.3. “Dual” score treatment outcome
comparisons
58 site-based and 7 site-independent raters participated in
the rater training and certiﬁcation program and were
qualiﬁed to score the MADRS in this study. Light's kappa
statistic for the two MADRS interviews used for IRR were
κ=0.619 and 0.809 respectively for all raters.
374 “dual” scores were available across the 5 study visits
(22.5% of all MADRS interviews). This sample of “dual” site-
based MADRS scores was comparable to all of the total
MADRS scores and change from baseline scores collected
from the entire study population during the study. Mean
total MADRS scores were 26.5710.8 for the 374 “dual”
scored site-based MADRS scores across all visits and
26.3710.5 for all 1664 collected scores (p=ns). There were
154 “dual” scores available at baseline, 39 at the post-
randomization week 1, 30 at week 2, 35 at week 4, and 116
“dual” scores available at week 6 (endpoint).
Mean total MADRS scores were comparable between site-
based and site-independent raters at all visits for the 354
paired “dual” scores. Mean total MADRS scores for the paired
154 “dual” baseline scores were 32.4575.98 (SD) for site-
based raters and 32.0276.15 for site-independent raters
(p=0.530). The mean total MADRS scores at week 6 for the
paired 116 “dual” scores were 19.52712.56 for the site-
based raters and 20.03711.92 (SD) for the site-independent
raters (p=0.748). The intra-class correlation was r=0.865 at
baseline (randomization) and improved to r=0.913, 0.945,
0.945, and 0.969 at the four subsequent post-randomization
visits (r=0.951 for all post-randomization visits combined).
Fig. 1 displays the scoring discordance between site-
based and site-independent raters for all 374 “dual” scored
interviews. Site-based “dual” scores deviated from site-
independent scores between 9 points higher and 7 points
lower at baseline and 10 points higher and 12 points lower
post-randomization. 23 of the 374 “dual” scores (6.2%) were
discordant using a total score deviation between site-based
and site-independent ratings of 46 points in either direc-
tion as the discordance range. Four of the 58 site-based
raters were identiﬁed as rater “outliers” and required rater
remediation during the study; no raters were removed from
the study.
Data for treatment outcome analyses were available from
85 pairs of “dual” MADRS interviews that were obtained at
baseline and week 6 (or last observation carried forward) for
the same patient. We calculated the outcome response
matches (response/non-response) achieved by the blinded,
site-independent raters for both the CX157 treatment group
and placebo group using the site-based treatment response
outcomes as the standard (Table 1). The CX157 group sensi-
tivity was 12/16 (75.0%%), speciﬁcity was 17/18 (94.4%), PPV
was 12/13 (92.3%), and NPV was 17/21 (81.0%%). The placebo
group sensitivity was 21/24 (87.5%), speciﬁcity was 26/27
Fig. 1 Total MADRS “dual” score deviations between site-based and site-independent raters (n=374). *Positive deviations (to the
right) reﬂect site-based scores that were higher than site-independent scores; alternatively, negative score deviations reﬂect site-
based scores that were lower than the “dual” site-independent scores.
Table 1 Comparison of treatment outcome responses of “dual” MADRS scores (n=85 pairs).
Site-based raters Site-independent raters
Treatment outcome Correct matchesa Incorrect matchesb
CX157 group responders 16 12 4
CX157 group non-responders 18 17 1
Placebo group responders 24 21 3
Placebo group non-responders 27 26 1
NOTE: Response is deﬁned as improvement of total MADRS score Z50% from baseline.
aReﬂects True Positives (Responders) or True Negatives (Non-Responders) relative to Site-based rater scores used as the standard.
bReﬂects False Positives (Non-Responders) or False Negatives (true responders) relative to site-based scores.
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Treatment response accuracy was 85.3% for the CX157 group,
92.2% for the placebo group, and 89.4% for the entire
population. Cohen's kappa coefﬁcient was 0.702 for the
CX157 group, 0.853 for the placebo group, and 0.786 for the
entire population.4. Discussion
In this study, “dual” ratings were used to compare site-
based MADRS interviews with blinded, site-independent
ratings based upon audio-digital recordings of the site-
based interviews. The primary purpose of the “dual” ratings
comparison was to identify rater “outliers” for remediation
or removal from the study.
As part of this program, we used these “dual” data to
evaluate the ability of the site-independent raters to
conﬁrm the site-based MADRS scores and the treatmentoutcome status. The site-independent raters were blinded
to all other study information and did not know the
study site, the study visit being assessed, or the site-based
rater's score. The “dual” scores revealed high correlations
between the site-based and site-independent raters at
all visits, a low discordance rate (6.2%), and high sensiti-
vity, speciﬁcity, and predictive values for the response/
non-response outcome status. The intra-class correlations
between site-based and independent raters increased at
each visit after baseline (r=0.865) and was ultimately
r=0.969 at the last visit.
Most of the 58 site-based raters were experienced with
the MADRS interview and had participated in surveillance
programs in the past. Hence, the high correlation observed
in this study was due in part to their participation in
previous programs prior to this study. Four of the site-
based raters were identiﬁed as “outliers” based upon a
higher rate of discordant “dual” scores identiﬁed early in
the study. These raters were remediated and their “dual”
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sistent with all other raters as the study proceeded. In fact,
the overall discordance rate improved during the study from
11.8% after 126 “dual” reviews, to 9.0% after 276 reviews,
and ﬁnally 6.2% at the end of the study (n=374). We believe
that the improving ICC and discordance rate noted during
the course of the study reﬂects the beneﬁcial effect of
remediation, awareness of the ongoing surveillance pro-
gram, and interviewing practice. It is likely that the mere
fact of being observed has a positive impact on the quality
of site-based interviews performed. The surveillance strat-
egy of “watching” provides as a type of Hawthorne effect
(McCarney et al., 2007). Future studies might consider a no-
surveillance comparison group to conﬁrm the beneﬁt of this
strategy.
The overall response accuracy of the blinded, site-
independent raters to match the site-based treatment
outcome status was 89.4% for the entire study population
(Cohen's kappa coefﬁcient=0.786). The placebo group
response accuracy using the MADRS was 92.2% in this study
and nearly identical to the ﬁndings of Leigh-Pemberton
et al. (2014) who reported 92.9% accuracy for the placebo
group using the HamD-17 in another depression study. These
ﬁndings conﬁrm site-based ratings reliability (precision) and
demonstrate that site-based raters can conduct competent
and very scorable MADRS interviews. The structured inter-
view guide (SIGMA) used in this study may have facilitated
the close “match” between site-based raters and blinded
independent raters, although unstructured formats have
also worked in other studies (Targum, unpublished data).
The mean interview length of the recorded MADRS inter-
views in this study was 25:1378:36 min at baseline
and 19:3177:49 for all post-randomization interviews
(p=0.0001). The MADRS interview length was signiﬁcantly
shorter after randomization because some patients improved
and endorsed fewer symptoms and may have required
less time to conduct the interview. The recorded baseline
(randomization) time is consistent with the ﬁndings of
Williams and Kobak (2008). In their reliability study con-
ducted as part of the development of the structured inter-
view guide for the MADRS (SIGMA), the mean interview length
was 25.8710.04 min (range 5–56 min) over two separate
visits. Williams and Kobak (2008) noted that the mean
interview length of the second MADRS interview was over
two minutes shorter than the ﬁrst interview (t=2.38,
p=0.02). Consequently, it is clear that the length of the
recorded MADRS interviews were largely consistent with the
expectations of the instrument authors.
Many of the site-based raters in this study had used the
audio-digital pen recording technology in the past and were
familiar with this assessment method. Overall, there were
minimal technical difﬁculties with this surveillance strategy
and the sites accepted and complied with the method
utilized. In our experience across multiple studies, “dual”
scoring of site-based ratings using the audio-digital pen
methodology is a relatively unobtrusive surveillance strat-
egy that can identify and remediate rater “outliers” during
a study.
These ﬁndings suggest that “dual” site-independent scor-
ing of recorded site-based interviews can be used to conﬁrm
ratings reliability and possibly enhance data integrity. How-
ever, there are several limitations that necessitate a cautiousinterpretation of the ﬁndings. These limitations include the
study design, treatment outcome, and the “dual” ratings
methodology itself. For instance, as noted above, the “dual”
ratings strategy employed in this study did not include a
comparison group without any surveillance such that some
sites (or raters) had no recording requirement while others
did. Hence, although it seems self-evident, it is not possible
to assert that “dual” ratings surveillance deﬁnitely improved
data integrity. Further, as the study did not achieve signal
detection for the candidate drug, it is not possible to
calculate a meaningful effect size comparison between
site-based and site-independent raters.
The “dual” ratings methodology implemented for this
speciﬁc study has some limitations that must be addressed.
First, only 22.5% of the study population had “dual” scores
for comparison. However, as noted in the results, there was
no statistically signiﬁcant difference between the total mean
MADRS scores of the “dual” ratings subpopulation (n=374)
compared to all 1664 MADRS interviews that were conducted
during the study. Second, a demonstration of “dual” con-
cordance between site-based and site-independent raters
does not necessarily convey scoring accuracy. Although it is
possible to determine whether “dual” scores are concordant,
it is not possible to determine whether the concordant
ratings are equally accurate or equally inaccurate. Of course,
scoring accuracy, in contrast to reliability or consistency is
an elusive target in CNS clinical trials. We have previously
reported that each different rating method, including
patient-reported outcomes have inherent limitations and
that no single rating method is best (Targum, 2011; Targum
et al., 2013). Third, the audio-digital recording method
chosen to obtain the “dual” scores in this study relies upon
the interview quality of the site-based rater and the
cooperation and information provided by the patient during
that interview. There were no video observations of the
patient in this study and no opportunity for the second,
independent rater to ask more questions.
There are alternative ratings methods that have been
used to obtain site-independent ratings that include video
resources or entirely separate “live” telephone interviews
by a second, remote rater. In our experience, video inter-
views can add an adverse measurement parameter for the
observed patient (anxiety) and adds cost and burden to the
site without substantially improving the “dual” ratings QA
objective or ratings reliability (Targum et al., 2013). Alter-
natively, an entirely separate interview conducted at a
different time yields informational and temporal variance
from the primary site-based rating and still requires good
interviewing skills and a cooperative subject. In previous
studies, we have reported that there was less correlation
between secondary telephone or video interviews with site-
based interview ratings than with the “dual” ratings strat-
egy (Targum, 2011).
Clearly, ratings precision is only one challenge confront-
ing randomized clinical trials. Ratings precision does not
necessarily convey validity. In previous studies, we have
reported that a patient's perception of his or her own
symptoms may be signiﬁcantly more severe than a clinician's
assessment at the beginning of a clinical trial and signiﬁ-
cantly less severe at the end (Targum et al., 2013).
In addition, both site selection and subject validation
prior to randomization are additional challenges that must
1765Audio-digital recordings used for independent conﬁrmation of site-based MADRS interview scoresbe addressed as part of a quality assurance/external review
program.
The capability to blindly conﬁrm ratings and conﬁrm
treatment response/non-response outcomes without knowl-
edge of the visit number or emerging adverse events suggest
that this method may have utility as a “shadow” study when
functional un-blinding is a concern. Despite the limitations
noted above, the “dual” ratings quality assurance method
may have broader applicability for studies that use sub-
jective measures, have multiple raters at multiple trial
sites, and wherever ratings precision is a concern.Contributors
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